Filing Details

Accession Number:
0001437749-20-023244
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-11-09 16:48:49
Reporting Period:
2020-11-06
Accepted Time:
2020-11-09 16:48:49
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1384101 Veracyte Inc. VCYT Services-Medical Laboratories (8071) 205455398
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1781127 Jr Walter John Hanna 6000 Shoreline Court
Suite 300
South San Francisco CA 94080
Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-11-06 21,250 $20.21 95,559 No 4 M Direct
Common Stock Disposition 2020-11-06 20,050 $43.40 75,509 No 4 S Direct
Common Stock Disposition 2020-11-06 1,200 $44.19 74,309 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2020-11-06 21,250 $0.00 21,250 $20.21
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
38,750 2029-02-27 No 4 M Direct
Footnotes
  1. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 11, 2020.
  2. Represents weighted average sales price. Sale prices for the transactions range from $43.00 to $44.00. Detailed information regarding the number of shares sold at each separate price will be provided to theSEC, the issuer or a shareholder upon request.
  3. Represents weighted average sales price. Sale prices for the transactions range from $44.03 to $44.41. Detailed information regarding the number of shares sold at each separate price will be provided to theSEC, the issuer or a shareholder upon request.
  4. The option became exercisable as to 25% of the shares on February 28, 2020, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.